SK&F 97426-A a more potent bile acid sequestrant and hypocholesterolaemic agent than cholestyramine in the hamster

      This paper is only available as a PDF. To read, Please Download here.


      SK&F 97426-A is a novel bile acid sequestrant which was selected for comparison with cholestyramine in vivo because of its superior in vitro bile acid binding properties. The effects of the two sequestrants on faecal bile acid excretion, plasma total cholesterol, VLDL + LDL and HDL cholesterol and triglyceride concentrations and on liver enzymes involved in the synthesis and metabolism of cholesterol were investigated in normocholesterolaemic hamsters. Four studies were conducted to determine the relative potencies of the two resins using a range of doses of the sequestrants over treatment periods of up to 2 weeks. Curves fitted to the resulting data allowed common maximum responses and separate ED50s to be calculated for each sequestrant. The maximum response of both sequestrants was to increase bile acid excretion by 352% and lower plasma total cholesterol by 37–58%. LDL + VLDL and HDL cholesterol were reduced by 56–75% and 25–41%, respectively. SK&F 97426-A was 3 times more potent than cholestyramine at increasing the excretion of bile acids in the faeces and 2.1–3.4-fold and 2.3–3.2-fold more potent at lowering total plasma cholesterol and LDL plus VLDL cholesterol, respectively. In some of the experiments SK&F 97426-A was also more potent than cholestyramine at lowering HDL cholesterol. Plasma triglycerides were also lowered by both sequestrants by up to 31 % after 1 week but the relative potency could not be determined. These HDL cholesterol and total triglyceride lowering effects of bile acid sequestrants in the hamster are known not to occur in people treated with cholestyramine. There were minimal differences between hamsters treated for 1 or 2 weeks in the relative potencies or ED50s calculated for the total plasma cholesterol, LDL + VLDL and HDL cholesterol. Both sequestrants may have been slightly more efficacious on these parameters after 2 weeks of treatment. Liver weights were reduced by about 15% by both sequestrants at 2% (w/w) in the diet for 1 week. The activities of the liver HMG-CoA reductase and cholesterol 7a-hydroxylase were increased as expected, whilst the activity of the acyl-CoA:cholesterol acyltransferase was reduced by both sequestrants at this dose. SK&F 97426-A was, therefore, 2–3-fold more potent as a bile acid sequestrant and hypocholesterolaemic agent than cholestyramine when tested in the hamster.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Hunninghake D.B.
        Bile acid sequestrant therapy.
        J. Drug Dev. 1990; 3: 205
        • Ast M.
        • Frishman W.H.
        Bile acid sequestrants.
        J. Clin. Pharmacol. 1990; 30: 99
        • Benson G.M.
        • Hickey D.M.B.
        Bile acid sequestrants: Past and future, Current Drugs: Antiatherosclerotic Agents, (Overview).
        in: 1991: B43-1359 (Current Patents Ltd, ISBN 0961-4680)
        • Benson G.M.
        • Haynes C.
        • Blanchard S.
        • Ellis D.
        In vitro studies to investigate the reasons for the low potency of cholestyramine and colestipol.
        J. Pharm. Sci. 1993; 82: 80
        • Garbutt J.T.
        • Kenney T.J.
        Effect of cholestyramine on bile acid metabolism in normal man.
        J. Clin. Invest. 1972; 51: 2781
        • Wood P.D.
        • Shioda R.
        • Estrich D.L.
        • Splitter S.D.
        Effect of cholestyramine on composition of duodenal bile in obese human subjects.
        Metabolism. 1972; 21: 107
        • Singhal A.K.
        • Finver-Sadowsky J.
        • McSherry C.K.
        • Mosbach E.H.
        Effect of cholesterol and bile acids on the regulation of cholesterol metabolism in hamster.
        Biochim. Biophys. Acta. 1983; 752: 214
        • Spady D.K.
        • Dietschy J.M.
        Sterol synthesis in vivo in 18 tissues of the squirrel monkey, guinea pig, rabbit, hamster, and rat.
        J. Lipid Res. 1983; 24: 303
        • Suckling K.E.
        • Benson G.M.
        • Bond B.
        • Gee A.
        • Glen A.
        • Haynes C.
        • Jackson B.
        Cholesterol lowering and bile acid excretion in the hamster with cholestyramine treatment.
        Atherosclerosis. 1991; 89: 183
        • Ochoa B.
        • Gee A.
        • Jackson B.
        • Suckling K.E.
        Regulation of cholesterol ester metabolism in the hamster liver.
        Biochim. Biophys. Acta. 1990; 1044: 133
        • Spady D.K.
        • Turley S.D.
        • Dietschy J.M.
        Rates of low density lipoprotein uptake and cholesterol synthesis are regulated independently in the liver.
        J. Lipid Res. 1985; 26: 465
        • Suckling K.E.
        • Boyd G.S.
        • Smellie C.G.
        Properties of a solubilised and reconstituted preparation of acylCoA:cholesterol acyltransferase from rat liver.
        Biochim. Biophys. Acta. 1982; 710: 154
        • Groot P.H.E.
        • Pearce N.J.
        • Suckling K.E.
        • Eisenberg S.
        Effects of cholestyramine on lipoprotein levels and metabolism in Syrian hamsters.
        Biochim. Biophys. Acta. 1991; 1123: 76
        • Planke M.O.
        • Olivier Ph.
        • Clavey V.
        • Marzin D.
        • Fruchart J.C.
        Aspects of cholesterol metabolism in normal and hypercholesterolaemic Syrian hamsters. Influ ence of Fenofibrate.
        Meth. Find. Exp. Clin. Pharm. 1988; 10: 575
        • Nikkari S.T.
        • Solakivi T.
        • Jaakkola O.
        The hyperlipidemic hamster as an atherosclerosis model.
        Artery. 1991; 18: 285
        • Mahley R.W.
        • Hui D.Y.
        • Innerarity T.L.
        • Weisgraber K.H.
        Two independent lipoprotein receptors on hepatic membranes of dog, swine, and man. Apo-B,E and ApoE receptors.
        J. Clin. Invest. 1981; 678: 1197
        • Packard C.J.
        • Shepherd J.
        The hepatobiliary axis and lipoprotein metabolism: Effects of bile acid sequestrants and ileal bypass surgery (review).
        J. Lipid Res. 1982; 23: 1081
        • Beher W.T.
        • Baker G.D.
        • Penney D.G.
        A comparative study of the effects of bile acids and cholesterol on cholesterol metabolism in the mouse, rat, hamster and guinea pig.
        J. Nutr. 1963; 79: 523